Accessibility Menu
CervoMed logo

CervoMed(NASDAQ) CRVO

Market Cap$34.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-66%
5 Year-94%
1 Year-69%
1 Month-30%
$2.62
+1.55%
+0.04Today
After hours$2.60-$0.02 (-0.76%)
CervoMed last closing stock price
MetricPriceDate
Last closeUSD 2.582026-07-31
CervoMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.01%USD 2.662026-07-24
1 month-30.08%USD 3.692026-07-01
3 month-30.46%USD 3.712026-05-01
Year to date-67.34%USD 7.902025-12-31
1 year-68.73%USD 8.252025-07-31
3 year-46.08%USD 4.792023-08-01
5 year-93.75%USD 41.272021-07-30
Since inception-66.01%USD 7.592023-08-17

CervoMed Financials at a Glance

Market Cap

$34.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$322.57K

Net Income (TTM)

-$30.04M

EPS (TTM)

-$3.27

P/E Ratio

-0.79

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$2.62

Volume

121,844.948

Open

$2.60

Previous Close

$2.60

Daily Range

$2.59 - $2.67

52-Week Range

$2.13 - $11.25

Estimated Earnings Date

Aug 14, 2026

CRVO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CervoMed

CervoMed develops medicines for brain diseases like dementia and stroke. Its main drug aims to help people with memory loss. The company focuses on treatments for older adults facing neurodegenerative conditions.

Brainy Business: Products and Services

  • Neflamapimod: An experimental oral drug for dementia with Lewy bodies, Alzheimer's, and stroke recovery. All current revenue comes from government grants supporting this research, not product sales.
  • Clinical Trials: Focused on dementia with Lewy bodies, primary progressive aphasia, stroke recovery, and amyotrophic lateral sclerosis (ALS).
  • Patent Portfolio: Covers drug uses, formulations, and manufacturing methods for neflamapimod.
  • Grant-Funded Research: All revenue comes from government grants, not product sales.

Growth Spurts and Strategic Moves

  • Launched Phase 2a and 2b clinical trials for neflamapimod in dementia with Lewy bodies in 2025.
  • Started new trials for primary progressive aphasia and stroke recovery in 2025.
  • Joined the UK’s EXPERTS-ALS platform for ALS drug evaluation in February 2026.
  • Secured FDA alignment for a planned Phase 3 trial in dementia with Lewy bodies in 2025.
  • Raised $50 million in private placement in April 2024 and $4.7 million in May 2025 through stock offerings.

What Makes CervoMed Stand Out

CervoMed targets specific brain diseases with few existing treatments. Its main drug candidate is, to the company's knowledge, the only one in its class to show clinical and biomarker improvements in both Phase 2a and Phase 2b trials. The company relies on grant funding and partnerships to advance its research.

Five Things You Need to Know

  • Grant revenue was $4.0 million in 2025, down 59% from 2024.
  • Net loss reached $27.0 million in 2025, up 66% from 2024.
  • Cash and marketable securities totaled $20.9 million at year-end 2025.
  • All revenue comes from government grants; no product sales to date.
  • Fifteen full-time employees as of December 2025.

Bottom Line

CervoMed is a small biotech focused on brain disease treatments, funded mainly by grants. Its future depends on clinical trial progress and securing new capital.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

15

CEO

John J. Alam, MD

Website

www.cervomed.com

Headquarters

Boston, MA 02116, US

CRVO Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-9642.13%

Net Income Margin

-9311.65%

Return on Equity

-136.08%

Return on Capital

-155.27%

Return on Assets

-198.75%

Earnings Yield

-1.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$34.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

13.53M

Volume

121.84K

Avg. Volume

5.54M

Financials (TTM)

Gross Profit

$322.57K

Operating Income

-$31.10M

EBITDA

-$30.04M

Operating Cash Flow

-$27.57M

Capital Expenditure

-$5.00

Free Cash Flow

-$27.57M

Cash & ST Invst.

$12.92M

Total Debt

$0.00

CervoMed Performance Analysis

CervoMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 7,144,872N/A
20242024-12-31USD 9,737,97436.3%
20252025-12-31USD 4,006,510-58.9%
CervoMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31-100.0%
Q12026-03-31N/A
CervoMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -11.20-39.5%
20232023-12-31USD -0.82-92.7%
20242024-12-31USD -2.02147.3%
20252025-12-31USD -2.9847.8%
CervoMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-25.0%
Q32025-09-30-20.0%
Q42025-12-31-3.6%
Q12026-03-311.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$34.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.33M

N/A

Employees

15

N/A

Net Income

-$7.96M

-62.7%

EBITDA

-$7.96M

-62.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$12.92M

-63.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.99%

N/A

Return on Invested Capital

-2.93%

N/A

Free Cash Flow

-$8.02M

-105.9%

Operating Cash Flow

-$8.02M

-105.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NTRBNutriband Inc.
$2.81-1.40%
LITSLite Strategy, Inc.
$0.98+1.84%
NRXPNRx Pharmaceuticals, Inc.
$3.24+2.86%
XBITXBiotech Inc.
$2.24+0.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About CRVO

What is the current price of CervoMed?

CervoMed is trading at $2.60 per share.

What is the 52-week range for CervoMed?

Over the past 52 weeks, CervoMed has traded between $2.13 and $11.25.

How much debt does CervoMed have?

As of the most recent reporting period, CervoMed reported total debt of $0.00.

How much cash does CervoMed have on hand?

CervoMed reported $7.94M in cash and cash equivalents in its most recent financial results.

What is CervoMed’s dividend yield?

CervoMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services